News

What would happen if all ophthalmic staff were allocated such a salary?

There has been growing concern within the medical industry that senior physicians can negatively impact patient care.

A new gene therapy could preserve vision in people with retinitis pigmentosa and might effectively treat other degenerative nerve disorders.

Experts break down the most prevalent falsities ophthalmologists believe about dispensaries, and why believing them are seriously hurting practice revenue.

In her latest blog, Donna Suter gives her advice on creating better communication with your patients.

Guidelines for Case Study Submissions

In her latest blog, Joy Gibb, ABOC, writes how ophthalmologists can fight UPP at the source-your patients.

Patients who are blind from retinitis pigmentosa continue to benefit from a safe retinal implant after 3 years, Ophthalmology reported

In his latest blog, Mark Packer, MD, reflects on ophthalmic pioneers of the past, and writes why controversy and challenging the norm is what drives the future of advancements.

Santen recently launched fixed-combination tafluprost and timolol (TAPTIQOM) in the United Kingdom.

Collaborations with practicing ophthalmologists have been crucial to nanotechnology discoveries pertaining to eye diseases, and in which drug can be delivered to the eye.

An age-stratified analysis of endothelial cell count in diabetic and non-diabetic corneas found no statistically significant difference between the groups. Since diabetes may damage the inner layer of the cornea, other variables that affect cell health must also be evaluated.

Forward-looking research in drug delivery and therapies filled the sessions at this year’s meeting of the Association for Research in Vision and Ophthalmology.

Targeting of Myo/Nog cells using a novel nanocarrier complex loaded with doxorubicin is showing promise as a treatment for reducing posterior capsule opacification.

While practice may not always make perfect (at least in this life), it definitely does “make better” not only in sports, but also in the operating room.

Combination treatment with squalamine lactate ophthalmic solution 0.2% and ranibizumab PRN resulted in improved visual function in patients with neovascular age-related macular degeneration compared with treatment with ranibizumab alone.

A novel anti-vascular endothelial growth factor agent, RTH258, produced rapid and sustained improvements in visual acuity and central subfield thickness and was non-inferior to aflibercept in a phase II trial.

New surveillance data on antibiotic resistance among ocular pathogens shows worrisome trends for some widely used drugs while resistance rates for some isolates were relatively stable.

Serial measurements of sirolimus blood concentrations after intravitreal injection show the maximum concentration achieved was below the level generally associated with systemic immunosuppression.

John Berdahl, MD, is the developer of Balance Goggles, eyewear intended to help regulate the pressure inside the eye.

The addition of phenylephrine 1%/ketorolac 0.3% injection to the irrigation bottle maintains pupil dilation and makes patients more comfortable intra- and postoperatively.

Degeneration of rods in eyes with RP leads to night vision problems and loss of rod-derived cone viability factor (RdCVF) that is necessary for cone survival. Replacing RdCVF may prevent cone degeneration and loss of central vision.

A whole-hearted commitment to building and designing a dispensary from the ground up is vital for its success, explain those who have first-hand experience.

In her debut blog, Georgette Pascale shares her must-have PR tips that every doctor must know to ensure a successful practice.

Find out how to improve your surgical work flow, reducing the total phaco time and total amount of fluid in cataract procedures while you stay very safe and efficient.

Does your state make the list?

Tell Ophthalmology Times what areas you wish we covered more by taking this short survey.

Retinal microglia contribute to rod demise in retinitis pigmentosa-a blinding hereditary retinal disease for which there is currently no approved treatment, according to a recent study.